// App-Quantinova.ai

4553 : Durable radiologic and clinical disease stability beyond PSA progression in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA).

Researchers

Presenter

  • Diletta Bianchini

Principal Investigators

  • Shahneen Kaur Sandhu

  • Amy Mulick Cassidy

  • Ajit Sarvadikar

  • Emilda Thompson

  • Joanne Hunt

  • Elizabeth Sheridan

  • Gerhardt Attard

  • Johann Sebastian De Bono

  • Andrea Zivi

  • Janusz Mezynski

  • Deborah Mukherji

  • Carmel Jo Pezaro

  • Alison Helen Reid

  • Nikhil Babu Oommen

  • David Olmos

  • Aurelius Gabriel Omlin

Medical Centers

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • The Institute of Cancer Research & The Royal Marsden, London, Spain

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • Institute for Cancer Research, London, United Kingdom

  • The Institute of Cancer Research, Sutton, United Kingdom

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • Royal Marsden Hospital, Dublin, Ireland

  • The Royal Marsden Hospital, London, United Kingdom

Locations

  • Ireland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved